Jodie Pope Morrison Sells 9,896 Shares of Q32 Bio (NASDAQ:QTTB) Stock

Q32 Bio Inc. (NASDAQ:QTTB) CEO Jodie Pope Morrison sold 9,896 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total transaction of $44,630.96. Following the sale, the chief executive officer owned 89,104 shares of the company’s stock, valued at $401,859.04. This represents a 10.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jodie Pope Morrison also recently made the following trade(s):

• On Tuesday, December 2nd, Jodie Pope Morrison sold 22,506 shares of Q32 Bio stock. The stock was sold at an average price of $3.46, for a total value of $77,870.76.

Q32 Bio Price Performance

QTTB traded down $0.20 during midday trading on Friday, reaching $4.56. 203,990 shares of the company’s stock traded hands, compared to its average volume of 164,705. The firm has a fifty day moving average of $3.78 and a two-hundred day moving average of $2.88. The stock has a market capitalization of $56.09 million, a price-to-earnings ratio of -1.33 and a beta of 0.16. Q32 Bio Inc. has a 52 week low of $1.35 and a 52 week high of $6.37.

Institutional Trading of Q32 Bio

A number of hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP purchased a new stake in shares of Q32 Bio in the 2nd quarter worth approximately $25,000. Acadian Asset Management LLC purchased a new position in Q32 Bio during the first quarter valued at $50,000. Two Sigma Investments LP bought a new stake in Q32 Bio in the third quarter worth $62,000. ADAR1 Capital Management LLC purchased a new stake in shares of Q32 Bio in the fourth quarter worth $66,000. Finally, AQR Capital Management LLC purchased a new stake in shares of Q32 Bio in the first quarter worth $68,000. 31.32% of the stock is owned by institutional investors.

Key Headlines Impacting Q32 Bio

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, providing a long?term constructive view that can support upside versus current levels. HC Wainwright Begins Coverage on Q32 Bio
• Neutral Sentiment: HC Wainwright published a multi?year forecast showing improving EPS over time and an eventual transition to modest profitability in FY2030 (EPS $0.11), which is a positive directional signal but depends on successful clinical and commercial execution.
• Negative Sentiment: The analyst model shows substantial near?term losses: Q4 2025 EPS of ($0.63) and FY2025–FY2028 EPS ranging from about ($2.91) to ($2.19). These projected deficits increase financing and execution risk and likely weigh on short?term investor sentiment.
• Negative Sentiment: Consensus full?year earnings remain deeply negative (current consensus ~($12.32) per share), indicating the market and other analysts expect much larger near?term losses than HC Wainwright’s more optimistic runway—this divergence may temper the impact of the Buy rating.

Analysts Set New Price Targets

QTTB has been the subject of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Q32 Bio in a report on Friday, January 9th. HC Wainwright assumed coverage on shares of Q32 Bio in a research report on Wednesday. They set a “buy” rating and a $13.00 price target on the stock. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Q32 Bio has an average rating of “Hold” and an average target price of $14.00.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.